Aim The present study aimed to evaluate the effect of quercetin in COVID-19 treatment. Methods This was a single-centre, prospective randomised controlled cohort study. Routine care versus QCB (quercetin, vitamin C, bromelain) supplementation was compared between 447 patients with at least one chronic disease and moderate-to-severe respiratory symptoms. Demographic features, signs, laboratory results and drug administration data of patients were recorded. The endpoint was that QCB supplementation was continued throughout the follow-up period from study baseline to discharge, intubation, or death. Results The most common complaints at presentation were fatigue (62.4%), cough (61.1%), anorexia (57%), thirst (53.7%), respiratory distress (51%) and chills (48.3%). The decrease in CRP, procalcitonin and ferritin levels was higher in the QCB group (all Ps were <0.05). In the QCB group, an increase in platelet and lymphocyte counts were higher (all Ps were <0.05). QCB did not reduce the risk of events during follow-up. Adjustments for statistically significant parameters, including the lung stage, use of favipiravir and presence of comorbidity did not change the results. While there was no difference between the groups in terms of event frequency, QCB group had more advanced pulmonary findings. QCB supplement is shown to have a positive effect on laboratory recovery. Conclusion We suggest that suboptimal bioavailability of QCB may explain this. So, we conclude that if a stable blood level can be achieved for QCB, it may make a difference in the treatment of COVID-19.

Objective To determine maternal and neonatal outcomes in pregnant women with COVID-19 Design Retrospective, descriptive study Setting A single-center managing pregnant women with COVID-19 Population or Sample Third-trimester pregnant women with a diagnosis of COVID-19 Methods A retrospective, single-center, descriptive study Main Outcome Measures The maternal and neonatal results of COVID-19 pregnant women were evaluated by looking at the following parameters: the concentrations of D-dimer, complete blood count, ferritin, C-reactive protein, lymphocytes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), neonatal umbilical blood gas analyzes, real-time RT-PCR tests, lung CT imaging, admission to (neonatal) intensive care unit. Results In the third trimester, 40 pregnant women with COVID-19 were included. The most common complaint was cough (50%). The most common symptom that accompanied cough was fever and shortness of breath. Thirty-four patients delivered by cesarean and 6 patients delivered vaginally. Two patients were taken to the intensive care unit because of respiratory distress. There were no maternal and fetal deaths. The patients were hospitalized for an average of 5 days. One patient was followed up without treatment, while all other patients were given hydroxychloroquine. In addition, azithromycin, oseltamivir, or lopinavir/ritonavir were added to some patients in addition to hydroxychloroquine. Conclusions The clinical features of pregnant women with COVID-19 are comparable compared to non-pregnant adults. Long-term results and comparative studies are needed in this regard.